In an early-phase clinical trial that included pancreatic cancer patients, pegylated recombinant human IL-10 induced promising anti-cancer immunity by expanding CD8+ cytotoxic T cell infiltration in the tumor microenvironment and reversing the MDSC-derived negative regulatory effect on effector immune system[59,60]. Here, IL10 is linked to pancreatic neoplasm.